i-FACTOR
-
Biologics
Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery
Data published in ClinicoEconomics and Outcomes Research show that the novel i-FACTOR is not only cost-effective compared to autograft in…
Read More » -
Biologics
Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today…
Read More » -
Biologics
Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide…
Read More » -
Biologics
Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data
WESTMINSTER, Colo., Nov. 18, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has…
Read More » -
Biologics
Cerapedics Announces i-FACTOR™ Peptide Enhanced Bone Graft Adopted by More than 150 Leading U.S. Hospitals
WESTMINSTER, Colo., Oct. 26, 2017 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that more than 150 leading U.S. hospitals have now…
Read More » -
Hospitals
Cerapedics Receives FDA Approval for i-FACTOR™ Peptide Enhanced Bone Graft in Cervical Spine Surgery
WESTMINSTER, Colo., Nov. 3, 2015 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, announced today the U.S. Food and Drug Administration (FDA) has approved…
Read More »